We are live on ! Find out more
DRNA

Dicerna Pharmaceuticals, Inc.
DRNA

Delisted

DRNA was delisted on the 27th of December, 2021.

Back to rankings

37 hedge funds and large institutions have $65.1M invested in Dicerna Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more capital invested

Capital invested by funds: $36.7M → $65.1M (+$28.5M)

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

3% more funds holding

Funds holding: 36 → 37 (+1)

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

Holders
37
Holders Change
+1
Holders Change %
+2.78%
% of All Funds
0.92%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
9
Increased
8
Reduced
10
Closed
8
Calls
$31K
Puts
–
Net Calls
+$31K
Net Calls Change
+$31K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$1.2M
2
EC
EcoR1 Capital
California
+$691K
3
Goldman Sachs
Goldman Sachs
New York
+$384K
4
MC
Matisse Capital
Oregon
+$364K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$351K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.2M
2
SM
Sabby Management
Florida
-$602K
3
PP
Paloma Partners
Connecticut
-$507K
4
6CM
683 Capital Management
New York
-$145K
5
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
-$37.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$14M – – –
RI
2
RTW Investments
New York
$12M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$8.46M -$3.2M -878,599 -37%
EC
4
EcoR1 Capital
California
$5.51M +$691K +190,000 +25%
6CM
5
683 Capital Management
New York
$4.37M -$145K -39,767 -5%
UBS Group
6
UBS Group
Switzerland
$3.54M +$1.2M +331,084 +117%
PAI
7
Palo Alto Investors
California
$2.88M – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$2.7M +$96.4K +26,500 +6%
Vanguard Group
9
Vanguard Group
Pennsylvania
$2.51M +$351K +96,338 +28%
EAM
10
Eventide Asset Management
Massachusetts
$2.17M – – –
OFM
11
Omega Fund Management
Massachusetts
$1.28M – – –
BCM
12
Bridgeway Capital Management
Texas
$968K +$273K +75,000 +80%
BlackRock
13
BlackRock
New York
$652K -$6.07K -1,669 -1%
Goldman Sachs
14
Goldman Sachs
New York
$606K +$384K +105,420 New
MC
15
Matisse Capital
Oregon
$575K +$364K +100,000 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$527K +$32.9K +9,047 +11%
Connor, Clark & Lunn Investment Management (CC&L)
17
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$397K -$37.5K -10,300 -13%
Deutsche Bank
18
Deutsche Bank
Germany
$297K +$188K +51,681 New
BC
19
Birchview Capital
Vermont
$259K +$91K +25,000 +125%
California Public Employees Retirement System
20
California Public Employees Retirement System
California
$236K – – –
Northern Trust
21
Northern Trust
Illinois
$207K -$761 -209 -0.6%
BCM
22
Bourgeon Capital Management
Connecticut
$190K -$21.8K -6,000 -15%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$164K – – –
Millennium Management
24
Millennium Management
New York
$158K +$100K +27,559 New
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
$157K -$17K -4,682 -15%
1
2

DRNA Hedge Fund Activity: Q3 2017 in Review

37 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q3 2017, worth a combined $65.1M — up 78% from $36.7M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new DRNA positions and 8 closed out — a net gain of 1 holder — while 8 added to existing stakes and 10 trimmed.

The largest buyer was UBS Group, adding an estimated $1.2M. The largest seller was Fidelity Investments, cutting an estimated $3.2M.

  • 37 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q3 2017, up from 36 in Q2 2017.
  • Funds reported $65.1M of Dicerna Pharmaceuticals, Inc. stock for Q3 2017, up 78% quarter-over-quarter.
  • 9 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q3 2017 and 8 closed out, a net change of +1 holder.
  • The largest Dicerna Pharmaceuticals, Inc. buyer in Q3 2017 was UBS Group, an estimated $1.2M added.
  • The largest Dicerna Pharmaceuticals, Inc. seller in Q3 2017 was Fidelity Investments, an estimated $3.2M sold.

Based on aggregated 13F filings for Q3 2017.